Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-16
    E.g., 2018-10-16

Archive Search

Pages

55 results
1:10 PM, Dec 30, 2016  |  BC Week In Review | Clinical News  |  Regulatory

Anagrelide CR regulatory update

Galena said FDA confirmed that a Phase III trial comparing anagrelide CR vs. best available therapy …
hydroxyurea. Galena said best available therapy will include a “sizable subpopulation” of patients treat with anagrelide
IR. Anagrelide CR is a controlled-release formulation of anagrelide, a small molecule that reduces platelet count …
12:00 AM, Aug 01, 2016  |  BC Week In Review | Clinical News  |  Clinical Results

Jakafi: Phase III data

patients receiving best available therapy. Patients received investigator’s choice of hydroxyurea, interferon, pegylated interferon, pipobroman, anagrelide
12:00 AM, Jan 18, 2016  |  BioCentury | Strategy

Shire's serial story

2014. Shire has no cancer therapies in its pipeline. It does market one hematology drug: Xagrid
anagrelide for essential thrombocythemia, a rare blood disease associated with the increased production of blood platelets …
12:00 AM, Aug 10, 2015  |  BioCentury | Strategy

Shire's M&A stepping stone

a single cancer product on the market: Baxalta's recently acquired leukemia drug Oncaspar and Shire's Xagrid
anagrelide, which is marketed for essential thrombocytopenia. Both generate about $100 million in annual sales. Enyedy …
model." Of Baxalta's four late-stage cancer programs, three are for hematological malignancies. Enyedy added that Xagrid
12:00 AM, Jun 22, 2015  |  BC Week In Review | Clinical News  |  Clinical Results

Anagrelide CR: Updated Phase II data

see BioCentury, Jan. 26 & June 15). Galena Biopharma Inc. (NASDAQ:GALE), Portland, Ore.   Product: Anagrelide
GALE-401 )   Business: Hematology   Molecular target: NA   Description: Controlled-release formulation of anagrelide
12:00 AM, Jun 15, 2015  |  BC Week In Review | Clinical News  |  Clinical Results

Anagrelide CR: Additional Phase II data

from the trial (see BioCentury, Jan. 26). Galena Biopharma Inc. (NASDAQ:GALE), Portland, Ore.   Product: Anagrelide
GALE-401 )   Business: Hematology   Molecular target: NA   Description: Controlled-release formulation of anagrelide
12:00 AM, Jan 26, 2015  |  BC Week In Review | Clinical News  |  Clinical Results

Anagrelide CR: Preliminary Phase II data

Society of Hematology meeting in San Francisco. Galena Biopharma Inc. (NASDAQ:GALE), Portland, Ore.   Product: Anagrelide
GALE-401 )   Business: Hematology   Molecular target: NA   Description: Controlled-release formulation of anagrelide
12:00 AM, Dec 08, 2014  |  BC Week In Review | Clinical News  |  Clinical Status

Anagrelide CR: Completed Phase II enrollment

achieve and maintain the target platelet count. Galena Biopharma Inc. (NASDAQ:GALE), Portland, Ore.   Product: Anagrelide
GALE-401 )   Business: Hematology   Molecular target: NA   Description: Controlled-release formulation of anagrelide
12:00 AM, Nov 17, 2014  |  BC Week In Review | Company News  |  Sales & Marketing

AOP Orphan sales and marketing update

AOP Orphan launched Thromboreductin anagrelide in Russia to treat essential thrombocythemia. The product comes in 0.5 …
12:00 AM, Sep 22, 2014  |  BC Week In Review | Clinical News  |  Clinical Status

Anagrelide CR: Phase II started

scientific literature or from previously approved products. Galena Biopharma Inc. (NASDAQ:GALE), Portland, Ore.   Product: Anagrelide
GALE-401 )   Business: Hematology   Molecular target: NA   Description: Controlled-release formulation of anagrelide

Pages